Brief: Can-Fite’s Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in Jan.; Topline Data Expected Q1 2022
07/12/2021 13:02
Dec 7 (Reuters) - Can Fite Biopharma Ltd CANF.TA :
* CAN-FITE’S PHASE III PSORIASIS STUDY TO COMPLETE 16-WEEK
TREATMENT OF LAST PATIENT IN JANUARY; TOPLINE DATA EXPECTED Q1
2022
Source text for Eikon: ID:nBw2pwHLMa
Further company coverage: CANF.TA
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage